The Gilead collaboration is fading fast, with partnership reimbursements down to $12 million from $28 million a year ago, and the loss per share came in wider than expected because of it. A $694 million cash position funds operations into 2029, with PEAK-1 enrollment for casdatifan wrapping up in two to three months.
Latest Activity
RCUS Coverage
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms. Five biotechs stand out as compelling acquisition candidates, each…
Biotechs Highlight 6 Stocks Insiders Are Buying Now
Biotech companies saw the most notable insider purchases of the past week. A Mexican billionaire also continued to build a stake.
Insider Buying at These Biotechs Is Huge
As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at these biotech companies.
With Arcus Partnership vs. Buyout, Gilead Moves Beyond Remdesivir COVID-19 Focus
In a world where investors are starving to find growth, many of the well established biotech leaders and many of the large pharmaceutical companies have been acquiring growth on top of their…